---
source: "2026 - Blood Flow Restriction Training Reduces Hemodynamic Load and Improves Cardiovascular Biomarkers in Runners with Exercise-Induced Hypertensio - Kim et al.md"
folder: "/GSE-Research/sports-research-papers/md/library/journals/Journal of Sports Science and Medicine/2026"
pages: 23
model: deepseek/deepseek-v4.1-flash-1017
words: 7618
---

<NATIVE_REASONING>
We need produce deep >=1000 words exact XML sections. Need answer based source. Need no betting lines. This is sports science physiology. Need cite exact [PAGE N] markers and verbatim quotes when source pages provided. We need infer page mapping from source text. It has page numbers 371-380 and 23 pages? Prompt says PAGES:23 but source only 10 journal pages perhaps PDF pages 1-? Need cite [PAGE N] exact markers maybe use journal page? They demand exact [PAGE N] markers. Source text includes page numbers 372, 373, etc. Need identify where quotes occur and assign [PAGE N] likely PDF page numbers? "PAGES: 23" maybe PDF has 23 pages? Source text only article pages 371-380, likely 10 pages. But task says PAGES: 23. We need be careful. In prior tasks, [PAGE N] markers correspond PDF pages, not journal page? But source text not annotated. We can cite [PAGE 1] etc? Need exact quotes. The text includes header 371, then 372, etc. We can cite [PAGE 1] for first source page? Hmm.

Need satisfy no fake equations. Formal LaTeX, units, assumptions, singularity/breakdown regimes. We can present actual equations from physiology: RPP = HR × SBP, pulse pressure = SBP − DBP, Karvonen HR = HR_rest + %HRR (HR_max − HR_rest). Also maybe ET-1/IL-6/CRP cascade not equation. Need mention units mmHg·bpm, mmHg, bpm, ml·kg−1·min−1. Need formal equations with assumptions and breakdown regimes. Need source citations exact [PAGE N] and verbatim quotes. We need decide page numbers. Let's map article pages:

First chunk "©Journal ... 371-380" and abstract. The first page likely journal page 371. Then page 372 starts at "Cardiovascular effects..." after received. Page 373 has Table1 and Methods? Actually source after "Kim et al. 373" etc. We can cite [PAGE 371], [PAGE 372], etc. The exact [PAGE N] markers can be journal page numbers? It says exact [PAGE N] markers and verbatim quotes. Use [PAGE 371] for page 371. But they may expect [PAGE 1], [PAGE 2]. Hm. Since source text has journal page numbers and 23 pages not 10, uncertain. We can use [PAGE 371] etc as exact page markers visible. The prompt says PAGES: 23 maybe the PDF includes 23 pages? But text only 10 pages. To avoid ambiguity, cite journal page numbers in brackets [PAGE 371], [PAGE 372], etc. That's exact from source. Good.

Need include >=400 word THINK_TRACE. Need total >=1000. We can write maybe 1600-2200 words. Need XML tags exactly. Must include sections. No betting lines. Need explain derivation, audit gray zones. Need multi-hop: BFR -> shear stress -> eNOS -> ET-1 reduction -> NF-kB/IL6 -> hs-CRP; hemodynamic load -> RPP/PP; NT-proBNP myocardial wall stress; NO null. Need discuss causal chain, assumptions, confounders, secondary analysis, nonrandomized, no AOP individualized, sample size. Need retrocausal genealogy: history of BFR/KAATSU, EIH definition Allison 1999, RPP as index, NT-proBNP, etc. Multi-week traps: week 1-2 adaptation/progression, fixed pressure, evening training, etc.

Need recursive theory of mind: "Crisis habit regression vs counter-trap vs clock." Interpret as athlete/clinician behavior under crisis, habit regression, counter-trap, time. Discuss how runner with EIH may regress to habitual high-volume running, or BFR protocol counter-trap of over-pressurization, clock (8 weeks, 20 min, 48h recovery, evening window). Need align with source. Need maybe not anthropomorphize. Mention adherence, supervision, no adverse events. Good.

Cross-layer veto adjudication: physical/biomechanical/weather veto proof. Need say physical: cuff pressure 250 mmHg, narrow cuff, skin color reperfusion >3 sec -> lower to 230; no adverse events. Biomechanical: treadmill incline/speed adjusted to 40-60% HRR, Bruce protocol, 20 min, twice weekly, 48h; no familiarization needed. Weather/environment: indoor 23°C, 40-50% RH, evening 18-21. Veto proof: if skin color fails, if HRR out of range, if temp/humidity deviate, if alcohol/strenuous exercise/caffeine not controlled -> data veto or session modification. Need say no direct weather field data; lab-controlled.

RLVR counterfactual vetoes: 3 verifiable scenarios + predictions. Need propose scenarios that would falsify causal claims. E.g., 1) Randomize to BFRT vs sham BFR with individualized AOP; if SBPmax reduction disappears, then fixed-pressure/ischemia not causal. Prediction: BFRT SBPmax lower by ≥? But no betting. We can predict direction not odds. 2) Measure FMD and ET-1 at multiple time points; if ET-1 decreases but FMD unchanged and hs-CRP unchanged, endothelial mediation veto. 3) Use NO metabolites with standardized nitrite/nitrate and diet; if no NO change but ET-1 decrease persists, NO-independent mechanism supported; if NO rises and ET-1 falls, mediation possible. Need verifiable. Could use crossover, blinded, AOP individualized. Need predictions. RLVR = Reinforcement Learning from Verifiable Rewards? Use "verifiable reward signal" maybe. Need not mention betting.

Need include formal equations and assumptions. Let's formulate:

\[
\mathrm{RPP}(t)= \mathrm{HR}(t)\,[\mathrm{beats\,min^{-1}}]\times \mathrm{SBP}(t)\,[\mathrm{mmHg}],\quad [\mathrm{mmHg\cdot beats\cdot min^{-1}}]
\]
Sometimes divided by 100 for presentation. Resting RPP RRPP, max MRPP. Assumption: SBP and HR measured simultaneously at same stage/peak; no arrhythmia or beat-to-beat mismatch. Breakdown: if HR sampled at different time than BP, or if BP artifact, RPP invalid; in arrhythmia average over beats.

\[
\mathrm{PP}(t)=\mathrm{SBP}(t)-\mathrm{DBP}(t), [\mathrm{mmHg}]
\]
Assumption: same arterial pressure measurement; DBP reliable. Breakdown: if DBP < 0? no. If cuff measurement error; if SBPmax after exercise vs peak.

Karvonen:
\[
HR_{target}=HR_{rest}+\%HRR\,(HR_{max}-HR_{rest}),\ [\mathrm{beats\,min^{-1}}]
\]
where %HRR is 0.40–0.60. Assumption: HRmax from GXT valid; resting HR stable; steady-state. Breakdown: if HRmax underestimated in runners? If beta-blockers; if arrhythmia; if HR drift. In source they use 40-60% HRR and 50/60.

Maybe occlusion pressure:
\[
P_{cuff}(w) = 250\ \mathrm{mmHg}\ \text{or}\ 230-300\ \mathrm{mmHg}
\]
But not equation. Better not.

Biomarker cascade:
\[
\mathrm{ET\text{-}1}\uparrow \Rightarrow \mathrm{NF\text{-}\kappa B}\uparrow \Rightarrow IL\text{-}6\uparrow \Rightarrow \mathrm{hs\text{-}CRP}\uparrow
\]
Not formal? It's qualitative. We can state as hypothesized pathway, not a ratio.

Need cite quotes:
- Abstract: "In the BFRTg, ET-1, hs-CRP, and NT-proBNP levels decreased after BFR training, while maximal systolic blood pressure decreased and VO₂max increased (all p < .05)." [PAGE 371]
- "Hemodynamic load also improved, as indicated by reductions in resting and maximal rate-pressure product (RPP) and pulse pressure during maximal exercise (all p < .05)." [PAGE 371]
- Methods: "BFR training was performed twice weekly for 20 minutes over 8 weeks." [PAGE 371? Abstract] Also methods [PAGE 373?]. The text after Table 1: "Runners who participated in the BFR exercise set their heart rate to 40-60% of their heart rate reserve (HRR) using data from the GXT and the Karvonen formula. Participants engaged in treadmill exercise for 20 minutes per session, twice weekly for 8 weeks with at least 48 hours between sessions..." [PAGE 374 maybe? Actually page 374 begins "ville, NC, USA" then methods. Let's map: Page 373 ends with "Morris-" and page 374 begins "ville, NC, USA." Then "Blood flow restriction exercise method" likely page 374. Quote is on page 374. Use [PAGE 374].
- Cuff pressure: "the exercise was paused, and the cuff pressure was lowered from 250 mmHg to 230 mmHg." This is on page 374. Use [PAGE 374].
- Table 2 on page 374.
- Results: "For Endothelin-1 (ET-1), the BFRTg showed a significant decrease from 1.32 ± 0.23 pre-intervention to 1.14 ± 0.33 post-intervention (p < 0.05)" [PAGE 375]
- "For hs-CRP, the BFRTg experienced a significant decrease from 0.93 ± 0.82 pre-intervention to 0.39 ± 0.23 post-intervention" [PAGE 375]
- "For NT-proBNP, the BFRTg changed from 32.3 ± 27.2 pre-intervention to 24.0 ± 18.6 post-intervention, while the non-BFRTg showed a significant increase from 20.2 ± 15.7 to 38.0 ± 39.6" [PAGE 376? Actually page 375 ends with "For NT-proBNP, the BFRTg changed..." and page 376 continues. Need quote maybe [PAGE 375] for first part. The quote spans pages. Use [PAGE 375] and [PAGE 376].
- NO: "For NO, the BFRTg changed from 78.7 ± 59.2 preintervention to 63.9 ± 64.6 post-intervention, and the nonBFRTg changed from 39.7 ± 13.6 to 38.1 ± 22.4; there was no significant interaction effect" [PAGE 376].
- Limitations: "cuff pressure was not individualized to AOP" [PAGE 377? Actually limitations on page 377? Let's map: Page 376 has Discussion start? Wait source: after Figures 2-5, "The present study was conducted..." then page 376 header. Then Discussion principal findings. Page 377 continues discussion. Limitations are on page 377-378. Quote "Finally, cuff pressure was not individualized to AOP, which is recommended in contemporary BFR guidelines." [PAGE 377] or [PAGE 378]? Let's inspect: The text around limitations appears after "These findings support the notion..." and before "Finally, cuff pressure..." That is page 378? The source page header "378 Cardiovascular effects..." appears after "differences in exercise" and before "reported adverse event rates..." Actually let's reconstruct page breaks:

Page 375: Table 3, Table 4, figures? It has page number 375 at top? The text "Kim et al. 375" appears before "Human Endothelin-1..."? Wait source:
- Page 374 begins "ville, NC, USA." then methods, Table 2, then "Kim et al. 375" then "Human Endothelin-1 QuantiGlo..." So page 375 starts with "Human Endothelin-1..." and includes results Table 3 and Table 4 and figures? Actually after Table 3 and Table 4, then Figures 2-5, then "The present study was conducted..." and "Discussion" and "Kim et al. 377" appears later. Let's scroll: Source has:
"Kim et al. 375
Human Endothelin-1..." Then blood analysis, stats, Results, Table3, Table4, Figures 2-5, "The present study was conducted..." then "Discussion" and "The principal findings..." Then "Kim et al. 377" appears after "reductions in ET-1, hs-CRP, and NT-proBNP. These findings support..." So page 376? Wait the header "Kim et al. 377" appears after a paragraph starting "The present study was conducted..." and before "these hemodynamic improvements..." Hmm.

Let's locate page numbers in source:
- "372 Cardiovascular effects..." after first page.
- "Kim et al. 373" after figure 1.
- "374 Cardiovascular effects..." after table 1? Actually source: Table 1, then text, then "Graded Exercise Test (GXT)" then page 374 header appears after "Morris-"? Let's see: In source, after "automated sphygmomanometer (Tango+, SunTech Medical, Morris-" then "374 Cardiovascular effects..." then "ville, NC, USA." So page 374 starts with "ville, NC, USA." Yes.
- "Kim et al. 375" appears after Table 2 and before "Human Endothelin-1 QuantiGlo..." So page 375 starts with Human Endothelin-1.
- "376 Cardiovascular effects..." appears after Table 4? Actually source: after Table 3 and Table 4, then figures 2-5, then "The present study was conducted..." then "Discussion" then "The principal findings..." then "Kim et al. 377" appears after "these hemodynamic improvements were accompanied..."? Wait source: after "Discussion" paragraph: "The principal findings... In addition, BFR training induced favorable changes... These findings support..." Then "Kim et al. 377" then "these hemodynamic improvements were accompanied by favorable biochemical adaptations." So page 376 ends with "These findings support our initial hypothesis..." and page 377 begins "these hemodynamic improvements..." Hmm but where is page 376 header? It should appear earlier. Source has "376 Cardiovascular effects of BFR in exercise-induced hypertension" before Table 4? Let's check: After Table 3, there is "376 Cardiovascular effects..." then Table 4, then values, then figures, then "The present study..." So page 376 includes Table 4 and figures and discussion start? Then "Kim et al. 377" after discussion first paragraph. Yes.
- "378 Cardiovascular effects..." appears after "differences in exercise" and before "reported adverse event rates..." So page 377 includes Discussion ET-1, hs-CRP, NT-proBNP, RPP/PP, NO; page 378 starts with "reported adverse event rates..." and includes limitations and conclusion? Actually limitations are on page 378. Then "Kim et al. 379" references. Page 380 references and key points.

Thus limitations quote "Finally, cuff pressure was not individualized to AOP..." is on page 378. Use [PAGE 378].

Need include "verbatim quotes" exact. We can quote short phrases. Need ensure exact spelling. Use quotes from source. For [PAGE 371] quote: "In the BFRTg, ET-1, hs-CRP, and NT-proBNP levels decreased after BFR training, while maximal systolic blood pressure decreased and VO₂max increased (all p < .05)." Exact? Source: "In the BFRTg, ET-1, hs-CRP, and NT-proBNP levels decreased after BFR training, while maximal systolic blood pressure decreased and VO₂max increased (all p < .05)." Yes.

Quote for RPP: "Hemodynamic load also improved, as indicated by reductions in resting and maximal rate-pressure product (RPP) and pulse pressure during maximal exercise (all p < .05)." Exact.

Quote methods: "Participants engaged in treadmill exercise for 20 minutes per session, twice weekly for 8 weeks with at least 48 hours between sessions" exact? Source: "Participants engaged in treadmill exercise for 20 minutes per session, twice weekly for 8 weeks with at least 48 hours between sessions to allow adequate physiological recovery and minimize cumulative physiological stress associated with BFR exercise." Use [PAGE 374].

Quote cuff: "If the skin color did not return from white to red within 3 seconds, this indicated excessive blood flow restriction; therefore, the exercise was paused, and the cuff pressure was lowered from 250 mmHg to 230 mmHg." [PAGE 374] exact.

Quote environment: "All testing and training sessions were conducted indoors at an ambient temperature of approximately 23°C and a relative humidity of approximately 40 - 50%." [PAGE 374] exact.

Quote ET-1: "For Endothelin-1 (ET-1), the BFRTg showed a significant decrease from 1.32 ± 0.23 pre-intervention to 1.14 ± 0.33 post-intervention (p < 0.05)" [PAGE 375] exact.

Quote hs-CRP: "For hs-CRP, the BFRTg experienced a significant decrease from 0.93 ± 0.82 pre-intervention to 0.39 ± 0.23 post-intervention (p < 0.05)" [PAGE 375] exact.

Quote NT-proBNP: "For NT-proBNP, the BFRTg changed from 32.3 ± 27.2 pre-intervention to 24.0 ± 18.6 post-intervention, while the non-BFRTg showed a significant increase from 20.2 ± 15.7 to 38.0 ± 39.6 (p < 0.05)" [PAGE 375-376]. Need exact: Source: "For NT-proBNP, the BFRTg changed from 32.3 ± 27.2  pre-intervention to  24.0  ±  18.6   post-intervention, while the non-BFRTg showed a significant increase from 20.2 ± 15.7 to 38.0 ± 39.6 (p < 0.05); there was a significant interaction effect between the two groups (p < 0.05) (Figure 4)." It spans page break? The quote begins on page 375 and ends page 376. Could cite [PAGE 375–376] but "exact [PAGE N] markers" maybe use [PAGE 375] [PAGE 376]. Use both.

Quote NO: "For NO, the BFRTg changed from 78.7 ± 59.2 preintervention to 63.9 ± 64.6 post-intervention, and the nonBFRTg changed from 39.7 ± 13.6 to 38.1 ± 22.4; there was no significant interaction effect" [PAGE 376].

Quote limitation: "cuff pressure was not individualized to AOP, which is recommended in contemporary BFR guidelines." [PAGE 378]. Also "no additional a priori sample size calculation was performed specifically for the present study" [PAGE 372]. Use.

Quote no adverse: "No adverse events were observed during the intervention period." [PAGE 374]. Good.

Need use "SI/information/probability units" maybe mention units for equations: mmHg·bpm, mmHg, bpm, ml·kg−1·min−1, pg·mL−1, mg·L−1? Source doesn't provide units for biomarkers? It says ET-1 pg/mL, hs-CRP maybe mg/L, NT-proBNP pg/mL, NO µmol/L? Source only says ET-1 reference range 0.401-2.83 pg/mL, hs-CRP and NT-proBNP no units in text. We can mention "where reported: ET-1 pg·mL−1; hs-CRP and NT-proBNP assay-specific; NO colorimetric assay with no unit specified in source." Better avoid inventing. Need "information/probability units" maybe for statistical: p-values are probabilities (dimensionless), partial eta squared dimensionless. Use η²_p. We can state.

Need "exact singularity/breakdown regimes" for equations. We can list:
- RPP: invalid when HR and SBP not temporally co-registered; with arrhythmia use averaged beats; if SBP measured after cuff deflation not peak, underestimates; if RPP divided by 100, unit must state.
- PP: invalid when DBP measurement error or if SBP/DBP from different arms/time; in maximal exercise PP can be distorted by movement artifact; if SBP is not true peak.
- Karvonen: invalid if HRmax from GXT is not maximal (runners with EIH may terminate before true HRmax? But GXT maximal?); breakdown if beta-blockers or arrhythmia; if HRR target set from estimated HRmax; if HR drift >5 bpm and treadmill speed/incline not adjusted.
- Biomarker cascade: not deterministic; if ET-1 assay CV 6.7%, changes near CV are noise; if hs-CRP <0.5 mg/L? no; if NT-proBNP influenced by renal function, age, exercise; if NO single timepoint and oxidized to nitrate; breakdown of mediation if no FMD.

Need "multi-hop derivation": Start with source observations: SBPmax decreased 223.8±9.0 to 182.2±16.6 in BFRTg vs 219.0±5.3 to 212.0±14.9 control [PAGE 375 table]. RPP max 362.2±37.3 to 288.9±35.4 vs 356.2±20.9 to 348.7±27.2 [PAGE 375]. PP max 130.0±12.0 to 95.0±18.0 vs 124.5±8.5 to 120.0±16.5 [PAGE 375]. ET-1 1.32 to 1.14 vs 1.23 to 1.26; hs-CRP 0.93 to 0.39 vs 0.73 to 1.33; NT-proBNP 32.3 to 24.0 vs 20.2 to 38.0; NO no interaction. VO2max 45.5 to 49.6 vs 47.8 to 48.1. Need maybe quote table? We can cite [PAGE 375] for Tables 3/4. The source table has exact numbers. Use as evidence.

Need "gray-zone audit": non-randomized, secondary analysis, control group habitual exercise, sample 28, no a priori sample size, multiple biomarkers, no AOP individualized, fixed pressures, no FMD, NO single timepoint, no long-term outcomes, medication not standardized, lifestyle confounders, no blinding, group allocation not randomized. Need note baseline SBPmax p=0.080, BFRTg slightly higher; regression to mean? But interaction significant. Need mention control NT-proBNP increased significantly and hs-CRP increased non-significantly, variability huge. Need mention no adverse events but underpowered for safety. Need mention "cuff pressure not individualized to AOP" and "absolute pressures 150-260 widely used" but still limitation.

Need "retrocausal genealogy": Historical lineage: KAATSU Japan, Abe 2006 Kaatsu-walk, Loenneke 2012, Patterson 2019 guidelines, Shimizu 2016 endothelial function, Green 2017 hemodynamic stimuli, EIH Allison 1999 definition, RPP index, NT-proBNP in endurance athletes Scharhag 2005, Kim et al 2020/2024 EIH mechanisms. Retrocausal: current findings retroactively reinterpret prior BFR as vascular/anti-inflammatory rather than purely hypertrophic; prior EIH marathon biomarker studies (Kim 2013) explain why NT-proBNP/ET-1 selected; multi-week traps: week 1 adaptation, week 2 transition, weeks 3-8 progressive; if too much pressure early -> excessive ischemia; if too little -> insufficient shear; if training evening only, circadian confound; if 48h insufficient -> cumulative fatigue. Need mention "fixed/absolute pressure rather than AOP" is a trap.

Need "recursive theory of mind": Crisis habit regression vs counter-trap vs clock. Let's interpret: In crisis, athlete defaults to habitual high-volume running despite EIH; clinician may over-rely on absolute cuff pressure; counter-trap is to assume lower pressure is always safer, but then insufficient shear; clock is 8-week, 20 min, twice weekly, 48h, evening 18-21. Need discuss adherence, supervision, real-time perfusion checks. Use source. It asks "Crisis habit regression vs counter-trap vs clock." We can frame as three failure modes:
1. Crisis habit regression: runner with EIH under stress returns to chronic endurance training, increases SBPmax/RPP, negating BFR.
2. Counter-trap: operator reacts to ischemic skin by lowering pressure too much (or too often) and loses the shear-stress stimulus; or over-pressurizes to force adaptation and risks ischemia. Source has explicit rule: if skin color not return within 3 sec, lower 250 to 230; not arbitrary.
3. Clock: 8 weeks, 2×20 min, 48h, evening; if schedule compressed or sessions clustered, recovery and circadian assumptions break. Need mention no adverse events, supervised.

Need "cross-layer veto adjudication": 
- Physical: absolute cuff pressure and skin perfusion rule; if skin color does not return in 3s, lower pressure; no adverse events. Veto proof: if rule violated, session invalid.
- Biomechanical: treadmill incline/speed adjusted to maintain HR 40-60% HRR; Bruce protocol 3-min stages; measurements at 2:30; if target HR not met, session modified. If runner changes gait due to BFR, HR/RPP may misattribute.
- Weather: indoor 23°C, 40-50% RH; if not controlled, hemodynamic responses confounded. Veto: environmental deviation invalidates comparison. No outdoor weather data; study design controls it.

Need "RLVR counterfactual vetoes": 3 scenarios:
1. Randomize 1:1 to BFRT vs sham BFR (same cuff, low pressure) with concealed allocation and individualized AOP, same HRR. Prediction: if SBPmax and MRPP reductions replicate only in BFRT, causal BFR-specific; if both improve equally, non-specific exercise/attention effect.
2. Add FMD and plasma nitrite/nitrate with standardized diet and multiple timepoints. Prediction: if ET-1 falls but FMD and NO metabolites unchanged, endothelial function mediation veto; if FMD improves with ET-1 fall, mediation supported.
3. Crossover with AOP-individualized pressures and weather/temperature controlled; measure 24h ABPM and NT-proBNP. Prediction: if NT-proBNP reduction tracks MRPP reduction and disappears when MRPP matched, hemodynamic load mediation; if NT-proBNP falls independent of MRPP, alternative myocardial mechanism.

Need maybe include predictions in terms of direction and measurable thresholds? Avoid betting odds. We can say "predicted sign and pattern" not probabilities. Maybe mention p<0.05? That's not betting. Good.

Need answer in XML. Need ensure exact tags. We can include LaTeX inside. Need no markdown? XML can contain text. We can use paragraphs. The <THINK_TRACE> must be >=400 words. Let's craft maybe 600 words. Total >1000. Desired oververbosity 5, but requirement >=1000. We'll do ~1800-2200 words.

Need mention "ZERO BETTING LINES" no spreads/odds. Ensure no "bet" words? "RLVR" includes reward. Avoid "betting" entirely except maybe not. We must not mention betting lines. Fine.

Let's write.

Need be precise with citations. We can write [PAGE 371], etc. Since source text pages. Use exact quotes. Be careful not to misquote. Use Unicode? Fine.

Potential issue: "SI/information/probability units" - I can say "All statistical p-values are probabilities in [0,1] and dimensionless; η²_p is dimensionless." Good.

Need "formal LaTeX equations, units, assumptions, and exact singularity/breakdown regimes." Include equations in separate block:
1. RPP.
2. PP.
3. Karvonen.
4. Maybe "Δ" operator for pre-post change:
\[
\Delta X = X_{post}-X_{pre}
\]
with units same as X; interaction via two-way repeated measures. Assumption. Breakdown if baseline different. But maybe enough.

5. Maybe "Cohen's" no.

Need "source operators and equations" section. State "The paper's operators are empirical contrast operators: pre-post Δ and Time×Group interaction; equations are standard hemodynamic identities." Then equations. Good.

Need mention "RPP values were divided by 100 for presentation" [PAGE 375 table note]. Quote: "RRPP and MRPP values were divided by 100 for presentation" [PAGE 376? Table note page 376]. The table note appears on page 376? Actually Table 4 note: "RRPP and MRPP values were divided by 100 for presentation" on page 376. Use [PAGE 376]. This is important for units. Good.

Need include "Table 3 changes" with numbers. Let's quote exact table values? Maybe not verbatim? We can paraphrase with citations. But requirement says when source pages provided, cite exact markers and verbatim quotes. We have several verbatim quotes. For table numbers, cite [PAGE 375]. Use exact numbers from table: SBPmax BFRTg 223.8 ± 9.0 pre to 182.2 ± 16.6 post; non 219.0 ± 5.3 to 212.0 ± 14.9; Table 3 p I <0.001 (0.218). MRPP 362.2 ± 37.3 to 288.9 ± 35.4 vs 356.2 ± 20.9 to 348.7 ± 27.2; PPmax 130.0 ± 12.0 to 95.0 ± 18.0 vs 124.5 ± 8.5 to 120.0 ± 16.5. Use [PAGE 375]. Good.

Need maybe mention VO2max 45.5 ± 9.5 to 49.6 ± 7.9 vs 47.8 ± 6.6 to 48.1 ± 7.6 [PAGE 375]. Good.

Need note baseline SBPmax p=0.080 from Table 1 [PAGE 373]. It's not significant but BFRTg higher. Good.

Need maybe mention "EIH defined by SBP ≥210 mmHg" quote: "Participants whose maximal systolic blood pressure (SBP) increased to ≥210 mmHg during the GXT were classified as having exercise-induced hypertension" [PAGE 372]. Use.

Need "study design" quote: "Group allocation was not randomized." [PAGE 372]. Use.

Need "secondary analysis" quote: "no additional a priori sample size calculation was performed specifically for the present study." [PAGE 372]. Use.

Need "limitations" quote: "Finally, cuff pressure was not individualized to AOP, which is recommended in contemporary BFR guidelines." [PAGE 378]. Also "no adverse events" [PAGE 374].

Need "KAATSU" historical: source says "KAATSU training was performed using the KAATSU C3 device" [PAGE 374]. Use.

Need "cuff width" quote: "large-sized pneumatic thigh cuffs (narrowwidth cuff; width ≈ 5 cm)" [PAGE 374]. Use.

Need "evening window" quote: "All training sessions were conducted in the evening between 18:00 and 21:00" [PAGE 374]. Use.

Need "ambient" quote above.

Need "48h" quote above.

Need "HRR" quote: "Runners who participated in the BFR exercise set their heart rate to 40-60% of their heart rate reserve (HRR) using data from the GXT and the Karvonen formula." [PAGE 374]. Use.

Need "Table 2" weekly progression: Week1 50% HRR alternating 150→220 mmHg; Week2 50% HRR cyclic 230-300, constant 250; Weeks3-8 60% HRR initial 5 min cyclic 230-300 then 15 min constant 250 [PAGE 374]. Use.

Need "NO" quote. Good.

Need "statistical" p-values. Good.

Need "RLVR" maybe "verifiable reward" no.

Need avoid "toy equations" like Force/Fatigue. Fine.

Let's plan final structure:

<THINK_TRACE>
Paragraph 1: Goal and source. Multi-hop chain. Cite abstract. Derivation: BFR protocol -> ischemia/reperfusion -> shear -> eNOS -> ET-1/NF-kB/IL6/hs-CRP; hemodynamic load -> RPP/PP; wall stress -> NT-proBNP; NO null. Explain why NO null doesn't break endothelial story (source cites Brinkley, Allen, Green). Mention units and equations. 
Paragraph 2: Gray-zone audit: nonrandomized, secondary, sample 28, no a priori power, multiple biomarkers, no AOP, fixed pressure, no FMD, single NO, lifestyle/meds, no long-term outcomes. But interaction effects and within-group changes. Distinguish causal vs associative.
Paragraph 3: Assumptions and breakdowns: RPP/PP/Karvonen; if temporal co-registration fails; if HRmax not true; if cuff pressure not AOP; if skin reperfusion rule. 
Maybe 500-600 words.

<SOURCE_OPERATORS_AND_EQUATIONS>
Formal equations and citations. Explain source's empirical operators: Δ, interaction. List equations. Include exact quotes. Breakdown regimes. ~500 words.

<RETROCAUSAL_GENEALOGY>
History and multi-week traps. ~300 words.

<RECURSIVE_THEORY_OF_MIND>
Crisis habit regression, counter-trap, clock. ~250 words.

<CROSS_LAYER_VETO_ADJUDICATION>
Physical/biomechanical/weather. ~250 words.

<RLVR_COUNTERFACTUAL_VETOES>
3 scenarios + predictions. ~300 words.

Total ~2100 words. Good.

Need no markdown outside XML. Use XML tags. Inside, can use LaTeX. Avoid unescaped & maybe use "and". XML text cannot contain raw &? We should avoid ampersands. Use "and" instead of &. In LaTeX, \mathrm{ET\text{-}1} has \text{-} okay. Ampersand in equations? Avoid. The tags are XML. Need escape < in text? Inside p-values "p < .05" contains < which in XML would be problematic. But this is not strict? We should use "p&lt;.05" or write "p less than .05". To be safe, use "p&lt;.05" or "p < 0.05" could break XML parsing. Since they likely parse tags, we should escape < as &lt;. But quotes with "p < .05" inside text? We can write p&lt;.05. For equations, use \lt? In LaTeX, < is fine? But XML parser might see. Use \text{<}? Hmm. Better avoid raw < in XML except tag delimiters. Use "p&lt;.05" in text. In LaTeX equations, use "\lt" not standard. Could write \(p<0.05\) but raw < inside. To be safe, use "p&lt;0.05". But in LaTeX, &lt; renders as <. We can use `p \lt 0.05`? LaTeX \lt exists? Not standard; use `p < 0.05` but XML issue. Since this is plain response, not strict XML parser? It might be. Use `p&lt;0.05` where needed. For quotes, exact verbatim includes `<`? We can write p &lt; .05 and note. But "verbatim" then altered. Maybe acceptable? Hmm.

Also ampersand in "Time × Group" fine. Use Unicode ×. No ampersand. "ET-1" fine. "VO₂max" fine.

Need escape `<` in "≥210" no issue. "p < .05" use "p&lt;.05". The quote "p < .05" becomes "p &lt; .05". It's not exact verbatim due entity but semantically same. Maybe okay. Could use "p less than .05" but not verbatim. I think XML entity is fine.

Need ensure no raw `&` in text. Use "and". In LaTeX, `\mathrm{mmHg\cdot bpm}` no &. Good.

Need maybe include `\eta_p^2` with subscript. Fine.

Need "formal LaTeX equations" with `\[ ... \]`. In XML text, `[` fine. `\` fine. `_` fine. `<` avoid. Use `\Delta X = X_{\mathrm{post}} - X_{\mathrm{pre}}`. Good.

Need cite exact [PAGE N] markers. Use brackets. Good.

Let's draft carefully.

Potential issue: "SI/information/probability units" - include: "RPP has dimensions pressure × frequency; in SI, mmHg·beats·min−1 is not SI but clinical unit. Convert 1 mmHg = 133.322 Pa, so RPP in Pa·s−1 after conversion." Could mention. "p-values are dimensionless probabilities in [0,1], η²_p dimensionless." Good.

Need "singularity/breakdown regimes" maybe use term "breakdown" explicitly. For RPP, "breakdown when HR and SBP are not simultaneous or when SBP is not peak; in arrhythmia, RPP is not a valid single-beat index." For PP, "breakdown when DBP is measured with different cuff or if SBPmax is post-exercise." For Karvonen, "breakdown if HRmax is not maximal or if beta-blockade/arrhythmia; if %HRR >1? Not." Good.

Need "multi-week traps": mention weeks 1-2 vs 3-8. If premature progression to 60% HRR or 250 mmHg constant before adaptation, excessive ischemia; if never progress, insufficient stimulus. The source protocol uses progressive pressurization and real-time perfusion checks. Cite Table 2 [PAGE 374]. Good.

Need "retrocausal genealogy" maybe term "retrocausal" in sense current result reinterprets prior mechanisms. Mention "KAATSU-walk" Abe 2006, Loenneke 2012, Patterson 2019, Shimizu 2016, Green 2017, Allison 1999, Kim 2020/2024. Source references. Use citations to [PAGE 371-372] and references [PAGE 378-379]. Good.

Need "recursive theory of mind" maybe "the athlete's internal model and the operator's internal model recursively update." Use "crisis habit regression" as under threat, athlete defaults to habitual training; "counter-trap" as clinician overcorrects; "clock" as protocol timing. Good.

Need "cross-layer veto adjudication" use "veto proof" maybe "A session is adjudicated invalid if..." Good.

Need "RLVR_COUNTERFACTUAL_VETOES" exactly 3 scenarios. Use numbered list. Predictions. Good.

Need no "betting lines". Fine.

Let's write final. Ensure word count >1000. I can count approximate. We'll be thorough.

Need maybe mention "RPP values divided by 100 for presentation" quote. Include.

Need exact quote for "No adverse events were observed during the intervention period." [PAGE 374]. Good.

Need exact quote "Group allocation was not randomized." [PAGE 372]. Good.

Need exact quote "no additional a priori sample size calculation was performed specifically for the present study." [PAGE 372]. Good.

Need exact quote "Finally, cuff pressure was not individualized to AOP, which is recommended in contemporary BFR guidelines." [PAGE 378]. Good.

Need exact quote "For NO... there was no significant interaction effect" [PAGE 376]. Good.

Need maybe quote "improvements in endothelial function do not necessarily coincide with elevations in basal NO levels." [PAGE 377]? Source: "While NO concentrations are typically expected to increase after exercise interventions (Arefirad et al., 2022), improvements in endothelial function do not necessarily coincide with elevations in basal NO levels." [PAGE 377]. Use.

Need "RPP and PP independent predictors" quote? Not necessary.

Need "Time × Group interaction" p values from figures: ET-1 p=0.025 (η²=0.178), hs-CRP p=0.047 (η²=0.143), NT-proBNP p=0.007 (η²=0.250), NO p=0.481 (η²=0.019). Use [PAGE 376] figures. Good. This strengthens.

Need "ET-1 reference range" quote: "coefficient of variation (CV) was 6.7% within a reference range of 0.401 - 2.83 pg/mL." [PAGE 375]. Use for assay precision. Good.

Need "hs-CRP and NT-proBNP CV <5%" [PAGE 375]. Use maybe.

Need "statistical" quote "A two-way repeatedmeasures ANOVA was used to examine the main effects of time and group, as well as the Time × Group interaction." [PAGE 375]. Use.

Need "Shapiro-Wilk" etc. Not necessary.

Let's craft final with escaped `<` as `&lt;`. Use `≥` fine. Use `×` fine. Avoid raw `&`. In quotes, "p &lt; .05" is okay. Use "p &lt; 0.05" etc.

Need "VO₂max" with subscript. Good.

Need "mmHg·bpm" units. Good.

Potential XML issue: `\text{-}` includes `-` fine. `\mathrm{ET\text{-}1}` okay. `\uparrow` fine. `\Rightarrow` fine. `\Delta` fine. `\eta_p^2` fine. `\%` fine.

Need final only XML sections. No preamble. Ensure tags exact. Good.

Let's produce. 

</NATIVE_REASONING>

<THINK_TRACE>
The source is a secondary analysis of an 8-week blood flow restriction training intervention in middle-aged male runners with exercise-induced hypertension, and the key multi-hop derivation is not a single “BFR lowers blood pressure” claim but a chained physiologic argument. First, the paper reports that EIH was defined operationally as maximal systolic blood pressure ≥210 mmHg during graded exercise testing: “Participants whose maximal systolic blood pressure (SBP) increased to ≥210 mmHg during the GXT were classified as having exercise-induced hypertension” [PAGE 372]. Second, the intervention is a low-to-moderate aerobic treadmill stimulus performed under intermittent or constant limb occlusion, twice weekly for 20 minutes over 8 weeks [PAGE 374]. Third, the proposed mechanism is repeated ischemia-reperfusion and increased endothelial shear stress, which the authors link to endothelial nitric oxide synthase activity, improved endothelial function, and reduced vascular tone [PAGE 377]. Fourth, the observed hemodynamic outcomes are reduced maximal systolic blood pressure, reduced rate-pressure product, and reduced pulse pressure during maximal exercise; the abstract states: “In the BFRTg, ET-1, hs-CRP, and NT-proBNP levels decreased after BFR training, while maximal systolic blood pressure decreased and VO₂max increased (all p &lt; .05)” [PAGE 371]. Fifth, the biomarker layer is interpreted as convergent: ET-1 is a vasoconstrictor and inflammatory mediator, hs-CRP is a systemic inflammatory marker, and NT-proBNP is a myocardial wall-stress marker. The authors explicitly propose that ET-1 activates NF-κB and increases IL-6, which in turn drives hepatic hs-CRP synthesis [PAGE 377]. Thus the multi-hop derivation is: BFR-induced shear/metabolic stress → endothelial functional change → lower ET-1 and lower inflammatory signaling → lower hs-CRP; simultaneously, lower maximal SBP and lower RPP/PP → lower myocardial oxygen demand and arterial load → lower NT-proBNP. The NO null result is not automatically a contradiction because the paper argues that “improvements in endothelial function do not necessarily coincide with elevations in basal NO levels” [PAGE 377]. 

The gray-zone audit is substantial. This is not a randomized trial: “Group allocation was not randomized” [PAGE 372]. It is a secondary analysis with no a priori power calculation: “no additional a priori sample size calculation was performed specifically for the present study” [PAGE 372]. The final sample is 28 men, with 16 in BFRTg and 12 in non-BFRTg [PAGE 372]. The control group was instructed to maintain habitual exercise but did not receive the structured BFR program [PAGE 373], so the contrast is BFR plus supervised low-to-moderate treadmill exercise versus habitual activity, not BFR versus identical exercise without occlusion. The paper also notes that cuff pressure was not individualized to arterial occlusion pressure: “Finally, cuff pressure was not individualized to AOP, which is recommended in contemporary BFR guidelines” [PAGE 378]. Multiple biomarkers were compared, and the authors acknowledge Type I error risk [PAGE 378]. NO was measured at a single time point, and flow-mediated dilation was not included [PAGE 378]. Medication use and blood pressure control were not strictly standardized [PAGE 378]. These gray-zone features mean the correct inference is mechanistically plausible and internally consistent, but not definitive causal isolation of BFR from supervised exercise, attention, regression to the mean, or unmeasured lifestyle change. The strongest internal signals are the Time × Group interactions: ET-1 p = 0.025, η²_p = 0.178; hs-CRP p = 0.047, η²_p = 0.143; NT-proBNP p = 0.007, η²_p = 0.250; NO p = 0.481, η²_p = 0.019 [PAGE 376]. The weakest links are the nonrandomized design, small sample, fixed absolute cuff pressures, and absence of direct vascular function measurement. The derivation therefore survives as a coherent physiologic hypothesis with supportive biomarker convergence, but it does not survive as proof of a unique BFR causal mechanism.
</THINK_TRACE>

<SOURCE_OPERATORS_AND_EQUATIONS>
The paper’s empirical operators are the pre-post change operator and the Time × Group interaction operator, not invented ratios. The statistical model is stated as “A two-way repeatedmeasures ANOVA was used to examine the main effects of time and group, as well as the Time × Group interaction” [PAGE 375]. The change operator is:

\[
\Delta X = X_{\mathrm{post}} - X_{\mathrm{pre}}
\]

with units identical to \(X\). The interaction operator is the difference of these changes between groups:

\[
\Delta_{\mathrm{interaction}} = \Delta X_{\mathrm{BFRTg}} - \Delta X_{\mathrm{nonBFRTg}}
\]

where \(\Delta_{\mathrm{interaction}}\) has the same units as \(X\). Statistical significance is reported as a probability \(p\), which is dimensionless and bounded in \([0,1]\), and as partial eta squared \(\eta_p^2\), which is dimensionless.

The first formal hemodynamic identity is rate-pressure product:

\[
\mathrm{RPP}(t) = \mathrm{HR}(t)\,[\mathrm{beats\cdot min^{-1}}] \times \mathrm{SBP}(t)\,[\mathrm{mmHg}]
\]

so RPP has clinical units of \(\mathrm{mmHg\cdot beats\cdot min^{-1}}\). In SI pressure units, since \(1\ \mathrm{mmHg}=133.322\ \mathrm{Pa}\), RPP can be converted to \(\mathrm{Pa\cdot s^{-1}}\) by multiplying by \(133.322/60\). The source notes that “RRPP and MRPP values were divided by 100 for presentation” [PAGE 376]. Assumption: HR and SBP are measured at the same exercise stage or at true peak effort. Breakdown regimes: if HR and SBP are not temporally co-registered, RPP is invalid; if SBP is measured after cuff deflation rather than at peak exercise, RPP underestimates myocardial load; in arrhythmia, a single-beat RPP is not a stable index and averaged beats are required. The paper reports maximal RPP falling from \(362.2 \pm 37.3\) to \(288.9 \pm 35.4\) in BFRTg versus \(356.2 \pm 20.9\) to \(348.7 \pm 27.2\) in non-BFRTg [PAGE 375].

The second identity is pulse pressure:

\[
\mathrm{PP}(t) = \mathrm{SBP}(t)\,[\mathrm{mmHg}] - \mathrm{DBP}(t)\,[\mathrm{mmHg}]
\]

with units of \(\mathrm{mmHg}\). Assumption: SBP and DBP are obtained from the same arterial pressure measurement and same time point. Breakdown regimes: if SBP and DBP come from different arms, different times, or different cuff sizes, PP is artifactually altered; if DBP is unreliable during maximal treadmill exercise because of movement artifact, PPmax is unstable. The source reports PPmax falling from \(130.0 \pm 12.0\) to \(95.0 \pm 18.0\) in BFRTg versus \(124.5 \pm 8.5\) to \(120.0 \pm 16.5\) in non-BFRTg [PAGE 375].

The third identity is the Karvonen target heart rate:

\[
\mathrm{HR}_{\mathrm{target}} = \mathrm{HR}_{\mathrm{rest}} + \%\mathrm{HRR}\left(\mathrm{HR}_{\mathrm{max}} - \mathrm{HR}_{\mathrm{rest}}\right)
\]

with units of \(\mathrm{beats\cdot min^{-1}}\). The source states: “Runners who participated in the BFR exercise set their heart rate to 40-60% of their heart rate reserve (HRR) using data from the GXT and the Karvonen formula” [PAGE 374]. Assumption: GXT-derived HRmax is a valid maximal value and resting HR is stable. Breakdown regimes: if HRmax is underestimated because the GXT terminated before true maximal effort, the target HR is too low; if beta-blockade or arrhythmia is present, HRR is not a valid intensity anchor; if treadmill speed and incline are not adjusted as HR drifts, the prescribed %HRR is not maintained. The protocol used 50% HRR in weeks 1–2 and 60% HRR in weeks 3–8 [PAGE 374].

The biomarker pathway is best treated as a qualitative directed network rather than a deterministic equation:

\[
\mathrm{ET\text{-}1}\uparrow \Rightarrow \mathrm{NF\text{-}\kappa B}\uparrow \Rightarrow IL\text{-}6\uparrow \Rightarrow \mathrm{hs\text{-}CRP}\uparrow
\]

The source supports this as a proposed cascade: ET-1 activates NF-κB, increases IL-6, and IL-6 induces hepatic hs-CRP synthesis [PAGE 377]. Assumption: the sampled circulating biomarkers reflect the relevant vascular and myocardial processes. Breakdown regimes: ET-1 assay precision was reported with a coefficient of variation of 6.7% within a reference range of 0.401–2.83 pg/mL [PAGE 375], so changes near assay noise cannot be overinterpreted; hs-CRP can be driven by nonvascular inflammation; NT-proBNP is influenced by age, renal function, and exercise status; NO is rapidly oxidized and a single time point is insufficient for dynamic endothelial function [PAGE 377–378]. The observed biomarker changes are: ET-1 decreased from \(1.32 \pm 0.23\) to \(1.14 \pm 0.33\) in BFRTg [PAGE 375]; hs-CRP decreased from \(0.93 \pm 0.82\) to \(0.39 \pm 0.23\) [PAGE 375]; NT-proBNP changed from \(32.3 \pm 27.2\) to \(24.0 \pm 18.6\) in BFRTg while non-BFRTg increased from \(20.2 \pm 15.7\) to \(38.0 \pm 39.6\) [PAGE 375–376]; NO showed “no significant interaction effect” [PAGE 376]. These are empirical operators with explicit units and explicit breakdown regimes, not toy ratios.
</SOURCE_OPERATORS_AND_EQUATIONS>

<RETROCAUSAL_GENEALOGY>
The retrocausal genealogy runs from KAATSU-style limb occlusion and low-load BFR hypertrophy work to contemporary vascular-health BFR research. The paper situates BFR within prior work showing effects on muscle hypertrophy, muscular endurance, and cardiorespiratory fitness, attributed to metabolic stress under transient limb ischemia and expression of mitochondrial and vascular endothelial growth factors [PAGE 371]. It cites Abe et al. 2006 on KAATSU-walk training, Loenneke et al. 2012 on low-intensity BFR meta-analysis, and Patterson et al. 2019 on BFR methodology and safety [PAGE 378–379]. The intervention itself was performed with the KAATSU C3 device and “large-sized pneumatic thigh cuffs (narrowwidth cuff; width ≈ 5 cm)” [PAGE 374]. This lineage matters because earlier BFR work was largely read as a hypertrophy or strength stimulus, whereas the present study retrospectively reframes BFR as a hemodynamic and endothelial intervention. The EIH lineage is equally important: Allison et al. 1999 supplied the ≥210 mmHg definition [PAGE 372], and the paper’s prior work linked EIH in runners to coronary plaque, arterial stiffness, and cardiac remodeling [PAGE 371–372]. The biomarker selection is retrocausally explained by prior marathon and ultramarathon studies showing ET-1 and NT-proBNP elevations in EIH runners [PAGE 377]. The multi-week traps are explicit in Table 2: week 1 is an adaptation phase at 50% HRR with alternating pressure-release cycles around 150–220 mmHg; week 2 is a transition at 50% HRR with cyclic 230–300 mmHg followed by constant ≈250 mmHg; weeks 3–8 progress to 60% HRR with initial cyclic loading then ≈15 minutes constant restriction at 250 mmHg [PAGE 374]. The trap is premature progression: too much pressure or too early constant occlusion can produce excessive ischemia, whereas too little pressure or excessive release can fail to generate the shear stimulus. A second trap is schedule compression: the protocol specifies at least 48 hours between sessions [PAGE 374], and clustering sessions would violate the recovery assumption. A third trap is circadian and environmental drift: all sessions were conducted in the evening between 18:00 and 21:00, indoors at approximately 23°C and 40–50% relative humidity [PAGE 374]. If those clocks are broken, the comparison loses internal validity.
</RETROCAUSAL_GENEALOGY>

<RECURSIVE_THEORY_OF_MIND>
The recursive theory-of-mind layer has three failure modes: crisis habit regression, counter-trap, and clock. Crisis habit regression is the athlete’s default under threat: a runner with EIH who feels pressure to maintain fitness may regress to habitual high-volume endurance training, which is precisely the exposure that repeatedly elevates exercise blood pressure and myocardial workload. The paper’s rationale warns that repeated high myocardial workload during routine training may accelerate myocardial hypertrophy or atherosclerosis over time [PAGE 377]. The counter-trap is the operator’s overcorrection: after seeing a pale limb or worrying about ischemia, the operator may lower cuff pressure so much that the shear-stress stimulus is lost, or conversely may over-pressurize to force adaptation. The source provides a concrete adjudication rule: “If the skin color did not return from white to red within 3 seconds, this indicated excessive blood flow restriction; therefore, the exercise was paused, and the cuff pressure was lowered from 250 mmHg to 230 mmHg” [PAGE 374]. That rule is a counter-trap against arbitrary pressure decisions. The clock is the protocol’s time structure: 20 minutes per session, twice weekly, 8 weeks, at least 48 hours between sessions, evening 18:00–21:00, and blood sampling after an overnight fast between 08:00 and 10:00 [PAGE 374]. The recursive mental model is: athlete adherence updates operator confidence; operator confidence updates pressure decisions; pressure decisions update the physiologic stimulus; the physiologic stimulus updates the biomarker and hemodynamic readout. If the athlete hides fatigue or the operator ignores the clock, the model collapses. The paper reports “No adverse events were observed during the intervention period” [PAGE 374], which supports feasibility but does not eliminate the need for the explicit reperfusion check and supervised progression.
</RECURSIVE_THEORY_OF_MIND>

<CROSS_LAYER_VETO_ADJUDICATION>
The physical-layer veto is the occlusion-perfusion rule. A session is not adjudicated as valid BFR if the limb remains blanched after release beyond the stated threshold; the protocol pauses and reduces pressure from 250 mmHg to 230 mmHg [PAGE 374]. The use of a narrow 5 cm cuff and KAATSU C3 device is part of the physical boundary condition [PAGE 374]. The biomechanical-layer veto is exercise-intensity control: treadmill incline and speed were adjusted to maintain the target HRR, with 40–60% HRR prescribed and 50% then 60% used across phases [PAGE 374]. If gait changes, if the runner grips rails, or if the treadmill speed is not adjusted as HR drifts, the mechanical and cardiovascular dose is no longer the intended dose. The GXT used the Bruce protocol with 3-minute stages and measurements at 2 minutes 30 seconds into each stage [PAGE 373], so peak SBP and RPP depend on stage timing and effort. The weather/environment-layer veto is laboratory climate control: “All testing and training sessions were conducted indoors at an ambient temperature of approximately 23°C and a relative humidity of approximately 40 - 50%” [PAGE 374]. If temperature, humidity, or time of day deviates, hemodynamic and biomarker comparisons are confounded. The paper does not provide outdoor weather exposure data, so the correct adjudication is that environmental weather is controlled by indoor laboratory conditions, not measured as a field variable. A further veto is pre-test behavioral control: participants were instructed to avoid alcohol for at least 24 hours and strenuous exercise the day before testing, and caffeine was restricted for at least 12 hours before physiological testing [PAGE 373]. If those behavioral gates fail, the biomarker and hemodynamic readouts are not cleanly attributable to the intervention.
</CROSS_LAYER_VETO_ADJUDICATION>

<RLVR_COUNTERFACTUAL_VETOES>
1. Randomized sham-BFR counterfactual. Randomize runners with EIH to BFRT versus sham BFR with the same treadmill time, same 40–60% HRR prescription, same cuff application, and concealed allocation, with individualized arterial occlusion pressure. Verifiable prediction: if the SBPmax and maximal RPP reductions are BFR-specific, the BFRT arm should show a greater pre-post reduction than sham; if both arms improve similarly, the current effect is a nonspecific supervised-exercise or attention effect. This counterfactual directly tests the nonrandomized design weakness quoted as “Group allocation was not randomized” [PAGE 372].

2. Vascular-mediation counterfactual. Add flow-mediated dilation and repeated plasma nitrite/nitrate sampling with standardized diet and multiple time points. Verifiable prediction: if ET-1 falls but FMD and NO metabolites do not change, the endothelial-mediation claim is vetoed and the ET-1 change must be attributed to another pathway; if FMD improves alongside ET-1 reduction, the endothelial pathway survives. This is necessary because the source itself notes that NO was assessed at a single time point and that FMD was not included [PAGE 378], and because “improvements in endothelial function do not necessarily coincide with elevations in basal NO levels” [PAGE 377].

3. Hemodynamic-load mediation counterfactual. Use a crossover or matched-exercise design in which maximal RPP is experimentally matched between conditions while NT-proBNP is measured at standardized times. Verifiable prediction: if NT-proBNP reduction tracks the reduction in maximal RPP and disappears when RPP is matched, the wall-stress mediation hypothesis is supported; if NT-proBNP falls independently of RPP, a separate myocardial or systemic mechanism is required. This tests the paper’s own chain linking reduced RPP and PP to reduced myocardial oxygen demand and arterial load [PAGE 377] and its NT-proBNP interpretation [PAGE 376–377].
</RLVR_COUNTERFACTUAL_VETOES>